Timing of buprenorphine adoption by privately funded substance abuse treatment programs: The role of institutional and resource-based interorganizational linkages

Journal of Substance Abuse Treatment

Volumn 42, Issue 1, 2012, Pages 16-24

  Savage, Sarah A ^a   Abraham, Amanda J ^a   Knudsen, Hannah K ^b   Rothrauff, Tanja C ^a   Roman, Paul M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adoption; Buprenorphine; Interorganizational linkages

Indexed keywords

BUPRENORPHINE;

ARTICLE; DRUG INDUSTRY; FUNDING; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH PROGRAM; INTERVIEW; OPIATE ADDICTION; PRIORITY JOURNAL; SUBSTANCE ABUSE;

BUPRENORPHINE; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DIFFUSION OF INNOVATION; HUMANS; INTERINSTITUTIONAL RELATIONS; LOGISTIC MODELS; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRIVATE SECTOR; SUBSTANCE ABUSE TREATMENT CENTERS; TIME FACTORS; UNITED STATES;

EID: 82455210910     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.06.009     Document Type: Article

References (59)

1. Abraham A.J., Knudsen H.K., Rothrauff T.C., Roman P.M. The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation. Journal of Substance Abuse Treatment 2010, 38:275-283.
2. Abraham A.J., Roman P.M. Early adoption of injectable naltrexone for alcohol use disorders: Findings in the private treatment sector. Journal of Studies on Alcohol and Drugs 2010, 71:460-466.
3. Alkhateeb F.M., Khanfar N.M., Clauson K.A. Characteristics of physicians who frequently see pharmaceutical sales representatives. Journal of Hospital Marketing & Public Relations 2009, 19:2-14.
4. Becker M.H. Sociometric location and innovativeness: Reformulation and extension of the diffusion model. American Sociological Review 1970, 35:262-282.
5. Byosiere P., Luethge D.J., Vas A., Salmador M.P. Diffusion of organizational innovation: Knowledge transfer through social networks. International Journal of Technology Management 2010, 49:401-420.
6. Coleman J.S., Katz S.E., Menzel H. Medical innovation 1966, Bobbs-Merrill, New York.
7. Ducharme L.J., Abraham A.J. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy 2008, 3:1-10.
8. Ducharme L., Knudsen H., Roman P. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment 2007, 32:321-329.
9. Ducharme L.J., Roman P.M. Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption. Journal of Substance Abuse Treatment 2009, 37:90-94.
10. Erickson C.L., Jacoby S.M. The effect of employer networks on workplace innovation and training. Industrial and Labor Relations Review 2003, 56:203-223.
11. Forman R.F., Bovasso G., Woody G. Staff beliefs about addiction treatment. Journal of Substance Abuse Treatment 2001, 21:1-9.
12. Friedmann P.D., Jiang L., Alexander J.A. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. Journal of Behavioral Health Services & Research 2010, 37:322-337.
13. Garner B.R. Research on the diffusion of evidence-based treatments within substance abuse treatment: A systematic review. Journal of Substance Abuse Treatment 2009, 36:376-399.
14. Gibbons D.E. Interorganizational network structure and diffusion of information through a health care system. American Journal of Public Health 2007, 97:1684-1692.
15. Godley S.H., Garner B.R., Smith J.E., Meyers R.J., Godley M.D. A large-scale dissemination and implementation model for evidence-based treatment and continuing care. Clinical Psychology: Science and Practice 2011, 18:67-83.
16. Goes J.B., Park S.H. Interorganizational links and innovation: The case of hospital services. Academy of Management 1997, 40:673-696.
17. Granovetter M. The strength of weak ties. American Journal of Sociology 1973, 78:1360-1380.
18. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 2000, 343:1290-1297.
19. Johnson R.E., Jaffe J.H., Fudula P.J. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association 1992, 267:2750-2755.
20. Kissin W., McLeod C., Sonnefeld J., Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. Journal of Addictive Diseases 2006, 25:91-103.
21. Knudsen H.K., Abraham A.J., Roman P.M. Adoption and implementation of medications in addiction treatment programs. Journal of Addiction Medicine 2011, 5:21-27.
22. Knudsen H.K., Roman P.M. Modeling the use of innovations in private treatment organizations: The role of absorptive capacity. Journal of Substance Abuse Treatment 2004, 26:51-59.
23. Knudsen H.K., Roman P.M., Ducharme L.D., Johnson A.J. Organizational predictors of pharmacological innovation adoption: The case of disulfiram. Journal of Drug Issues 2005, 35:553-568.
24. Knudsen H.K., Ducharme L.J., Roman P.M. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment 2006, 30:363-373.
25. Knudsen H.K., Abraham A.J., Johnson J.A., Roman P.M. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2009, 37:307-312.
26. Koch A.L., Arfken C.L., Schuster C.R. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Dependence 2006, 83:274-278.
27. Bridging the gap between practice and research: Forging partnerships with community based drug and alcohol treatment 1998, 27-55. National Academy Press, Washington, DC. S. Lamb, M.R. Greenlick, D. McCarty (Eds.).
28. Lichstein P.R. Impact of pharmaceutical company representatives on internal medicine residency programs. Archives of Internal Medicine 1992, 152:1009-1013.
29. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., Ziedonis D. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005, 100:1090-1100.
30. Ling W., Smith D. Buprenorphine: Blending practice and research. Journal of Substance Abuse Treatment 2002, 23:87-92.
31. Lintzeris N., Bell J., Bammer G., Jolley D.J., Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002, 97:1395-1404.
32. Long J.S., Freese J. Regression models for categorical dependent variables using Stata 2006, Stata Press Publication, College Station, TX.
33. Mansfield E. Technological change 1971, W.W. Norton, New York.
34. McCormick B.B., Tomlinson G., Brill-Edwards P., Detsky A.S. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. Journal of the American Medical Association 2001, 286:1994-1999.
35. Mee-Lee D.L., Gartner L., Miller M.M., Shulman G.D., Wilford B.B. Patient placement criteria for the treatment of substance-related disorders 1996, Chevy Chase, MD, ASAM. 2nd ed.
36. Moore G.K. Crossing the chasm: Marketing and selling high-tech products to mainstream customers 1991, Harper Business, New York.
37. National Association of Addiction Treatment Providers About NAATP Retrieved on June 17, 2011. http://www.naatp.org/about/index.php.
38. National Institute on Drug Abuse About NIDA Retrieved on June 17, 2011, from. http://www.nida.nih.gov/about/aboutnida.html.
39. Nohria N., Eccles R.G. Networks and organizations 1992, Harvard Business School Press, Boston.
40. Oser C.B., Roman P.M. A categorical typology of naltrexone-adopting private substance abuse treatment centers. Journal of Substance Abuse Treatment 2008, 34:433-442.
41. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., Gessa G.L. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 2000, 60:39-50.
42. Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology 1996, 49:1373-1379.
43. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., Ladewig D. Double-blind placebo trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence 2001, 62:97-104.
44. Pittaway L., Robertson M., Munir K., Denyer D., Neely A. Networking and innovation: A systematic review of the evidence. International Journal of Management Reviews 2004, 5/6:137-168.
45. Polanyi M. The tacit dimension 1966, Routledge & KeganPau, London.
46. Powell W. Neither market nor hierarchy: Network forms of organization. Research in organizational behavior 1990, 12:295-336. JAI Press, Greenwich, CT. B.M. Staw, L.L. Cummings (Eds.).
47. Powell W.W., Koput K.W., Smith-Doerr L. Interoganizational collaboration and the locus of innovation: Networks of learning in technology. Administrative Science Quarterly 1996, 41:116-145.
48. Rieckmann T., Daley M., Fuller B.E., Thomas C.P., McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. Journal of Substance Abuse Treatment 2007, 32:207-215.
49. Roman P.M., Abraham A.J., Rothrauff T.C., Knudsen H.K. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2010, 38:S44-S52.
50. Rogers E.M. Diffusion of innovations 2003, Free Press, New York. 5th ed.
51. Roman P.M., Johnson A.J. Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment 2002, 22:1-8.
52. Saxon A.J., McCarty D. Challenges in the adoption of new pharmacotherapies for addiction to alcohol and other drugs. Pharmacology & Therapeutics 2005, 108:119-128.
53. Thomas C.P., Reif S., Haq S., Wallack S.S., Hoyt A., Ritter G.A. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services 2008, 59:909-916.
54. Thomas J.B., Trevino L.K. Information processing in strategic alliance building: A multiple-case approach. Journal of Management Studies 1993, 30:779-814.
55. Vittinghoff E., McCulloch C.E. Relaxing the rule of ten events per variable in logistic and cox regression. American Journal of Epidemiology 2007, 165:710-718.
56. Wallack S.S., Thomas C.P., Martin T.C., Chilingerian J., Reif S. Substance abuse treatment organizations as mediators of social policy: Slowing the adoption of a congressionally approved medication. Journal of Behavioral Health Services & Research 2010, 37:64-78.
57. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift?. Journal of the American Medical Association 2000, 283:373-380.
58. Westphal J.D., Gulati R., Shortell S.M. Customization or conformity? An institutional and network perspective on the content and consequences of TQM adoption. Administrative Science Quarterly 1997, 42:366-394.
59. Zuckerman H.S., D'Aunno T.A. Hospital alliances: Cooperative strategy in a competitive environment. Health Care Management Review 1990, 15:21-30.